$AYTU
AYTU BIOPHARMA, INC Stock $aytu

$aytu Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-K Financial Statement

#000114420417046061 Filed on August 31, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2017
Revenue	$1.080M	$840.0K	$3.222M
YoY Change	54.73%	-10.64%	25.72%
Cost Of Revenue	$290.0K	$350.0K	$1.417M
YoY Change	52.63%	6.06%	48.09%
Gross Profit	$790.0K	$490.0K	$1.804M
YoY Change	54.9%	-18.33%	12.39%
Gross Profit Margin	73.15%	58.33%	56.0%
Selling, General & Admin	$4.620M	$3.740M	$17.44M
YoY Change	-19.01%	18.73%	104.78%
% of Gross Profit	584.81%	763.27%	966.76%
Research & Development	$140.0K	$190.0K	$959.9K
YoY Change	-50.0%	-93.38%	-84.34%
% of Gross Profit	17.72%	38.78%	53.2%
Depreciation & Amortization	$650.0K	$2.100M	$4.365M
YoY Change	-20.94%	377.27%	398.94%
% of Gross Profit	82.28%	428.57%	241.91%
Operating Expenses	$5.140M	$4.320M	$23.35M
YoY Change	-9.9%	-32.61%	-3.79%
Operating Profit	-$4.350M	-$3.830M	-$20.13M
YoY Change	-27.09%	-34.08%	-7.28%
Interest Expense	$110.0K	-$1.650M	$2.534M
YoY Change	-73.52%	-17.5%	-53.85%
% of Operating Profit
Other Income/Expense, Net			-$2.383M
YoY Change			-63.2%
Pretax Income	-$4.250M	-$6.750M	-$22.51M
YoY Change	-25.7%	-55.88%	-20.12%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$4.250M	-$6.750M	-$22.51M
YoY Change	-25.76%	-55.88%	-20.13%
Net Earnings / Revenue	-393.52%	-803.57%	-698.67%
Basic Earnings Per Share
Diluted Earnings Per Share	-$425.0M	-$1.850B	-$9.660B
COMMON SHARES
Basic Shares Outstanding	4.022M shares	13.84M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.000M	$800.0K	$800.0K
YoY Change	55.56%	-91.21%	-91.21%
Cash & Equivalents	$7.000M	$802.3K	$800.0K
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$400.0K	$400.0K	$400.0K
YoY Change	-50.0%	33.33%	33.33%
Inventory	$1.200M	$1.312M	$1.300M
Prepaid Expenses
Receivables	$1.200M	$528.0K	$500.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.700M	$3.029M	$3.000M
YoY Change	51.56%	-70.07%	-70.3%
LONG-TERM ASSETS
Property, Plant & Equipment	$600.0K	$647.3K	$600.0K
YoY Change	100.0%	179.68%	200.0%
Goodwill		$238.4K
YoY Change		7.89%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$9.231M	$0.00
YoY Change	-100.0%	-12.5%	-100.0%
Total Long-Term Assets	$11.50M	$11.97M	$12.00M
YoY Change	-16.89%	-15.84%	-15.49%
TOTAL ASSETS
Total Short-Term Assets	$9.700M	$3.029M	$3.000M
Total Long-Term Assets	$11.50M	$11.97M	$12.00M
Total Assets	$21.20M	$15.00M	$15.00M
YoY Change	4.95%	-38.38%	-38.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.700M	$2.220M	$2.200M
YoY Change	-32.0%	-4.4%	-37.14%
Accrued Expenses	$1.600M	$782.5K	$1.100M
YoY Change	220.0%	-34.63%	-8.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.500M	$3.610M	$3.600M
YoY Change	-59.77%	-64.27%	-64.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.40M	$7.400M	$7.400M
YoY Change	165.12%	76.19%	76.19%
Total Long-Term Liabilities	$11.40M	$7.400M	$7.400M
YoY Change	165.12%	76.19%	76.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.500M	$3.610M	$3.600M
Total Long-Term Liabilities	$11.40M	$7.400M	$7.400M
Total Liabilities	$14.90M	$11.00M	$11.00M
YoY Change	14.62%	-22.86%	-23.08%
SHAREHOLDERS EQUITY
Retained Earnings		-$69.07M
YoY Change		48.34%
Common Stock		$73.07M
YoY Change		28.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.400M	$4.000M	$4.000M
YoY Change
Total Liabilities & Shareholders Equity	$21.20M	$15.00M	$15.00M
YoY Change	4.95%	-38.39%	-38.27%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2017
OPERATING ACTIVITIES
Net Income	-$4.250M	-$6.750M	-$22.51M
YoY Change	-25.76%	-55.88%	-20.13%
Depreciation, Depletion And Amortization	$650.0K	$2.100M	$4.365M
YoY Change	-20.94%	377.27%	398.94%
Cash From Operating Activities	-$4.220M	-$3.270M	-$13.83M
YoY Change	-20.83%	22.47%	29.74%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$60.00K	$111.6K
YoY Change	-100.0%	-94.5%	-55.87%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$600.0K	-$3.420M
YoY Change	-100.0%	-117.29%	-14.71%
Cash From Investing Activities	$0.00	$540.0K	-$3.530M
YoY Change	-100.0%	-111.84%	-33.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$739.9K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.44M	60.00K	10.19M
YoY Change	1611.48%	-99.09%	-38.84%
NET CHANGE
Cash From Operating Activities	-4.220M	-3.270M	-13.83M
Cash From Investing Activities	0.000	540.0K	-3.530M
Cash From Financing Activities	10.44M	60.00K	10.19M
Net Change In Cash	6.220M	-2.670M	-7.170M
YoY Change	-219.16%	330.65%	-1124.29%
FREE CASH FLOW
Cash From Operating Activities	-$4.220M	-$3.270M	-$13.83M
Capital Expenditures	$0.00	-$60.00K	$111.6K
Free Cash Flow	-$4.220M	-$3.210M	-$13.94M
YoY Change	-20.9%	103.16%	27.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q4	dei	Entity Public Float EntityPublicFloat	10500000	USD
CY2017	dei	Trading Symbol TradingSymbol	AYTU
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	528039	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	162427	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	1312221	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	524707	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	310760	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	215558	USD
CY2017Q2	aytu	Prepaid Research And Development Related Party PrepaidResearchAndDevelopmentRelatedParty	0	USD
CY2016Q2	aytu	Prepaid Research And Development Related Party PrepaidResearchAndDevelopmentRelatedParty	121983	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	3028562	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	10120227	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	647254	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	231430	USD
CY2017Q2	aytu	Core And Developed Technology Net CoreAndDevelopedTechnologyNet	1337333	USD
CY2016Q2	aytu	Core And Developed Technology Net CoreAndDevelopedTechnologyNet	1159736	USD
CY2017Q2	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	77667	USD
CY2016Q2	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	1353375	USD
CY2017Q2	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	164037	USD
CY2016Q2	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	194472	USD
CY2017Q2	us-gaap	Goodwill Goodwill	238426	USD
CY2016Q2	us-gaap	Goodwill Goodwill	221000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	296611	USD
CY2016Q2	aytu	Prepaid Research And Development Related Party Noncurrent PrepaidResearchAndDevelopmentRelatedPartyNoncurrent	213471	USD
CY2016Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2888	USD
CY2016Q2	us-gaap	Assets Assets	24343007	USD
CY2017Q2	aytu	Accrued Compensation Current AccruedCompensationCurrent	339704	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1451	USD
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2017Q2	us-gaap	Liabilities Liabilities	10998701	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	82	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	73069463	USD
CY2017Q2	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69069729	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46561425	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	3999816	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14998517	USD
CY2016Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8215	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	275992	USD
CY2016Q2	us-gaap	Liabilities Liabilities	14257754	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	19	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	56646659	USD
CY2016Q2	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	10085253	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24343007	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	802328	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	23346826	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-21704397	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7176648	USD
CY2016Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	4109	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8054190	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9231072	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10549797	USD
CY2017Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0	USD
CY2016Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	5379675	USD
CY2017Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	6673	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	1041362	USD
CY2017	aytu	Products And Services Revenue ProductsAndServicesRevenue	3221590	USD
CY2016	aytu	Products And Services Revenue ProductsAndServicesRevenue	2050838	USD
CY2017	us-gaap	Licenses Revenue LicensesRevenue	0	USD
CY2016	us-gaap	Licenses Revenue LicensesRevenue	511607	USD
CY2017	us-gaap	Revenues Revenues	3221590	USD
CY2016	us-gaap	Revenues Revenues	2562445	USD
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	1417355	USD
CY2016	us-gaap	Cost Of Revenue CostOfRevenue	957076	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	959857	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6127772	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-323.70
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-48.30
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-28180084	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-22508304	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6475687	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2383068	USD
CY2016	us-gaap	Interest Expense InterestExpense	5491486	USD
CY2017	us-gaap	Interest Expense InterestExpense	2534358	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-20125236	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8517592	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17442627	USD
CY2016	aytu	Research And Development Related Party ResearchAndDevelopmentRelatedParty	191991	USD
CY2017	aytu	Research And Development Related Party ResearchAndDevelopmentRelatedParty	387960	USD
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	466024	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	87057	shares
CY2016	us-gaap	Operating Expenses OperatingExpenses	24266842	USD
CY2017	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	165131	USD
CY2016	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	307704	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1265125	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	7500000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1708771	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	664707	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-195427	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	485265	USD
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	95202	USD
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-155330	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	493217	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	698237	USD
CY2017	aytu	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-861226	USD
CY2016	aytu	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	1004427	USD
CY2017	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	4200	USD
CY2016	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-10875	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-511607	USD
CY2017	aytu	Payments For Deposits Investing Activities PaymentsForDepositsInvestingActivities	0	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2016	aytu	Payments For Deposits Investing Activities PaymentsForDepositsInvestingActivities	-1998	USD
CY2017	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	0	USD
CY2016	us-gaap	Proceeds From Contributions From Parent ProceedsFromContributionsFromParent	5000000	USD
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	200000	USD
CY2017	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	0	USD
CY2016	us-gaap	Payments Of Debt Restructuring Costs PaymentsOfDebtRestructuringCosts	29754	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	298322	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	5396024	USD
CY2017	aytu	Adjustment To Additional Capital Issuance Of Warrants Related To Convertible Promissory Note AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote	0	USD
CY2016	aytu	Adjustment To Additional Capital Issuance Of Warrants Related To Convertible Promissory Note AdjustmentToAdditionalCapitalIssuanceOfWarrantsRelatedToConvertiblePromissoryNote	136828	USD
CY2017	aytu	Debt Instrument Convertible Beneficial Conversion Feature Net Of Accretion DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion	0	USD
CY2016	aytu	Debt Instrument Convertible Beneficial Conversion Feature Net Of Accretion DebtInstrumentConvertibleBeneficialConversionFeatureNetOfAccretion	4943073	USD
CY2017	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	218494	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	2502092	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	902946	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	182759	USD
CY2017	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	212809	USD
CY2016	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-12572	USD
CY2017	aytu	Warrant Derivative Liability Related To Issuance Of Convertible Promissory Notes WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes	0	USD
CY2016	aytu	Warrant Derivative Liability Related To Issuance Of Convertible Promissory Notes WarrantDerivativeLiabilityRelatedToIssuanceOfConvertiblePromissoryNotes	102931	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13829652	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10657449	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	111608	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	252932	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3534538	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5303925	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10187542	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16662503	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	701129	USD
CY2016Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8054190	USD
CY2015Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7353061	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	877542	USD
CY2017	aytu	Amortization Of Beneficial Conversion Feature AmortizationOfBeneficialConversionFeature	0	USD
CY2016	aytu	Amortization Of Beneficial Conversion Feature AmortizationOfBeneficialConversionFeature	4943073	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	355031	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5369	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4364680	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	874789	USD
CY2017	aytu	Amortization Of Prepaid Research And Development Due To Related Parties AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties	335454	USD
CY2016	aytu	Amortization Of Prepaid Research And Development Due To Related Parties AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties	121983	USD
CY2017	aytu	Primsol Business Purchase Included In Primsol Payable PrimsolBusinessPurchaseIncludedInPrimsolPayable	0	USD
CY2016	aytu	Primsol Business Purchase Included In Primsol Payable PrimsolBusinessPurchaseIncludedInPrimsolPayable	1077000	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1265125	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	7500000	USD
CY2017	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	221024	USD
CY2017	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	750000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	6000000	USD
CY2017	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	-1071707	USD
CY2017	aytu	Natesto Business Purchase Included In Natesto Payable NatestoBusinessPurchaseIncludedInNatestoPayable	0	USD
CY2016	aytu	Natesto Business Purchase Included In Natesto Payable NatestoBusinessPurchaseIncludedInNatestoPayable	5379675	USD
CY2017	aytu	Warrant Derivative Liability To Issuance Of Registered Offering Placement Agent Warrants WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants	0	USD
CY2016	aytu	Warrant Derivative Liability To Issuance Of Registered Offering Placement Agent Warrants WarrantDerivativeLiabilityToIssuanceOfRegisteredOfferingPlacementAgentWarrants	297317	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	246000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	112000	USD
CY2017	us-gaap	Depreciation Depreciation	134000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7922000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8672000	USD
CY2016	us-gaap	Depreciation Depreciation	51000	USD
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	44000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	426000	USD
CY2017Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	0	USD
CY2016Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1041000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400	pure
CY2017	us-gaap	Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0	USD
CY2016	us-gaap	Income Tax Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary IncomeTaxReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	-1674000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	100000	USD
CY2016	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	6000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0302	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0303	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0051	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0003	pure
CY2017	aytu	Effective Income Tax Rate Reconciliation Percentage Interest On Convertible Debt EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt	0.00	pure
CY2016	aytu	Effective Income Tax Rate Reconciliation Percentage Interest On Convertible Debt EffectiveIncomeTaxRateReconciliationPercentageInterestOnConvertibleDebt	0.0027	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3519	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3077	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0.00	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Equity In Earnings Losses Of Unconsolidated Subsidiary EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary	0.0594	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0045	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0002	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-7653000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9581000	USD
CY2017	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-681000	USD
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-853000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	116000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	7000	USD
CY2017	aytu	Effective Income Tax Rate Reconciliation Interest On Cnvertible Debt EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt	0	USD
CY2016	aytu	Effective Income Tax Rate Reconciliation Interest On Cnvertible Debt EffectiveIncomeTaxRateReconciliationInterestOnCnvertibleDebt	75000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Gross Current DeferredTaxAssetsGrossCurrent	0	USD
CY2016Q2	us-gaap	Deferred Tax Assets Gross Current DeferredTaxAssetsGrossCurrent	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	3000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	5000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15435000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9202000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1559000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	606000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1362000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	327000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	0	USD
CY2016Q2	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	360000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	75000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	153000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	174000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	192000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses	17000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses	15000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	19369000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11305000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	19369000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11305000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	445000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	139000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	120000	USD
CY2015Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	5200000	USD
CY2015Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	401000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	103000	USD
CY2017	aytu	Placement Agents Cash Fee Percentage PlacementAgentsCashFeePercentage	0.08	pure
CY2017	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	20000	USD
CY2016Q1	aytu	Warrants Issued To Purchase Of Common Stock WarrantsIssuedToPurchaseOfCommonStock	1113	shares
CY2016Q1	aytu	Warrants Exercise Price Per Share WarrantsExercisePricePerShare	156.00
CY2016Q2	aytu	Warrants Issued To Purchase Of Common Stock WarrantsIssuedToPurchaseOfCommonStock	1129	shares
CY2016Q2	aytu	Warrants Exercise Price Per Share WarrantsExercisePricePerShare	96.00
CY2017	aytu	Unrecognized Share Based Compensation Expenses UnrecognizedShareBasedCompensationExpenses	775000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	127000	USD
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y9M22D
CY2017Q2	aytu	Share Based Compensation Share Warrants Outstanding ShareBasedCompensationShareWarrantsOutstanding	286049	shares
CY2017Q2	aytu	Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice	50.29
CY2016Q2	aytu	Share Based Compensation Share Warrants Outstanding ShareBasedCompensationShareWarrantsOutstanding	110108	shares
CY2016Q2	aytu	Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice	124.02
CY2017	aytu	Class Of Warrant Or Rights Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm	P4Y2M23D
CY2017	aytu	Share Based Compensation Share Warrants Issued On Registered Offering ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering	301014	shares
CY2017	aytu	Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering	20077	shares
CY2017	aytu	Share Based Compensation Share Warrants Issued On Registered Offeringweighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice	37.2
CY2017	aytu	Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offeringweighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice	15
CY2015	aytu	Class Of Warrant Or Rights Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm	P4Y8M16D
CY2016	aytu	Share Based Compensation Share Warrants Issued On Convertible Promisory Notes ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotes	1115	shares
CY2016	aytu	Share Based Compensation Share Warrants Issued On Convertible Promisory Notes Weighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotesWeightedAverageExercisePrice	156
CY2016	aytu	Share Based Compensation Share Warrants Issued On Convertible Promisory Notestwo ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryNotestwo	1129	shares
CY2016	aytu	Share Based Compensation Share Warrants Issued On Convirtible Note Holders ShareBasedCompensationShareWarrantsIssuedOnConvirtibleNoteHolders	15279	shares
CY2016	aytu	Share Based Compensation Share Warrants Issued On Convertible Promisory Two Notesweighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnConvertiblePromisoryTwoNotesweightedAverageExercisePrice	96
CY2016	aytu	Share Based Compensation Share Warrants Issued On Convertible Note Holdersweighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnConvertibleNoteHoldersweightedAverageExercisePrice	120
CY2016	aytu	Class Of Warrant Or Rights Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm	P2Y11M1D
CY2015Q2	aytu	Share Based Compensation Share Warrants Outstanding ShareBasedCompensationShareWarrantsOutstanding	444	shares
CY2015Q2	aytu	Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice	1087.20
CY2015Q3	aytu	Placement Agents Cash Fee Percentage PlacementAgentsCashFeePercentage	0.08	pure
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	824831	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	824831	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187098	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187098	shares
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4021822	shares
CY2017	us-gaap	Gain Loss On Investments GainLossOnInvestments	-61519	USD
CY2016	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	1040000	USD
CY2017	aytu	Primsol Business Purchase Included In Primsol Payable Gross PrimsolBusinessPurchaseIncludedInPrimsolPayableGross	1250000	USD
CY2016	aytu	Primsol Business Purchase Included In Primsol Payable Gross PrimsolBusinessPurchaseIncludedInPrimsolPayableGross	1250000	USD
CY2017	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	221000	USD
CY2016	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	221000	USD
CY2017	us-gaap	Standardized Measure Of Discounted Future Net Cash Flow Relating To Proved Oil And Gas Reserves Accretion Of Discount StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount	173000	USD
CY2016	us-gaap	Standardized Measure Of Discounted Future Net Cash Flow Relating To Proved Oil And Gas Reserves Accretion Of Discount StandardizedMeasureOfDiscountedFutureNetCashFlowRelatingToProvedOilAndGasReservesAccretionOfDiscount	173000	USD
CY2016	us-gaap	Gain Loss On Investments GainLossOnInvestments	-971629	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-414570	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	925232	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000000	USD
CY2016	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	2012991	USD
CY2017	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding; On August 25, 2017, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 20 shares outstanding (herein referred to collectively as the Reverse Stock Splits). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.
CY2017Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	38263	shares
CY2017	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	16.31
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2017Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	19341	shares
CY2017	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	16.40
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2502000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000	USD
CY2016	aytu	Share Based Compensation Share Warrants Issued On Registered Offering ShareBasedCompensationShareWarrantsIssuedOnRegisteredOffering	86667	shares
CY2016	aytu	Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offering ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOffering	5474	shares
CY2016	aytu	Share Based Compensation Share Warrants Issued On Registered Offeringweighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnRegisteredOfferingweightedAverageExercisePrice	120.00
CY2016	aytu	Share Based Compensation Share Warrants Issued On Placement Agents For Registered Offeringweighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedOnPlacementAgentsForRegisteredOfferingweightedAverageExercisePrice	120.00
CY2017	aytu	Share Based Compensation Share Warrants Issued As Part Of Settlement ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlement	4402	shares
CY2017	aytu	Share Based Compensation Share Warrants Issued As Part Of Settlement Weighted Average Exercise Price ShareBasedCompensationShareWarrantsIssuedAsPartOfSettlementWeightedAverageExercisePrice	80.00
CY2017	aytu	Share Based Compensation Share Warrants Excercised Weighted Average Exercise Price ShareBasedCompensationShareWarrantsExcercisedWeightedAverageExercisePrice	15.00
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include valuation allowances, stock-based compensation, warrant valuation, purchase price allocation, valuation of contingent consideration, sales returns and allowances, useful lives of fixed assets, collectability of accounts receivable, and assumptions in evaluating impairment of definite and indefinite lived assets. Actual results could differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	aytu	Share Based Compensation Share Warrants Excercised ShareBasedCompensationShareWarrantsExcercised	-149552	shares
CY2016Q3	aytu	Common Stock Option Repricing Program Description CommonStockOptionRepricingProgramDescription	Board of Directors approved a common stock option repricing program whereby previously granted and unexercised options held by our then current employees, consultants and directors with exercise prices above $120.00 per share were repriced on a one-for-one basis to $64.60 per share
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	34000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	74000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	318000	USD
CY2017Q2	us-gaap	Contractual Obligation ContractualObligation	16517000	USD
CY2017Q2	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	914000	USD
CY2017Q2	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	603000	USD
CY2017Q2	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	2500000	USD
CY2017Q2	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	5000000	USD
CY2017Q2	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	0	USD
CY2017Q2	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	7500000	USD
CY2017	aytu	Warrants Modified WarrantsModified	175522	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.20
CY2017Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	25541	shares
CY2017Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.00
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	23000	USD
CY2017Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	149552	shares
CY2017Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2200000	USD
CY2017	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	At the insistence of the underwriters of the offering, all outstanding noteholders had signed lockup agreements which granted them an extra 10% on the conversion, increasing it to 130% of shares calculated by dividing such Note balance by $96.00
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	173000	USD
CY2016Q4	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3000	USD
CY2017Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	11969955	USD
CY2016Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	14222780	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	75214	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2220400	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2322605	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	782536	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1197106	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	15616452	USD
CY2016	aytu	Stock Subscription Payment StockSubscriptionPayment	5000000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	200000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10090849	USD
CY2016	aytu	Issuance Of Stock Issued During Periodvalue IssuanceOfStockIssuedDuringPeriodvalue	4237874	USD
CY2016	aytu	Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing	2059895	USD
CY2016	aytu	Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing To Placement Agents For Over Allotment Option AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption	20493	USD
CY2016	aytu	Adjustment For Rounding Of Value Due To Conversion AdjustmentForRoundingOfValueDueToConversion	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	902946	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2502092	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	724613	USD
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	509996	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	596434	USD
CY2017	aytu	Issuance Of Stock Issued During Periodvalue IssuanceOfStockIssuedDuringPeriodvalue	3671581	USD
CY2017	aytu	Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancing	3470646	USD
CY2017	aytu	Adjustments To Additional Paid In Capital Warrants Issued In Connection With Equity Financing To Placement Agents For Over Allotment Option AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithEquityFinancingToPlacementAgentsForOverAllotmentOption	172629	USD
CY2017	aytu	Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts Adjustmentstoadditionalpaidincapitalwarrantsissuedinconnectionwithequityfinancingtoplacementagentsnoncashissuancecosts	292630	USD
CY2017	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1931123	USD
CY2017	aytu	Adjustmentstoadditionalpaidincapitalwarrantamendments Adjustmentstoadditionalpaidincapitalwarrantamendments	64690	USD
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1837500	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	648933	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	29754	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1202231	USD
CY2017	us-gaap	Restricted Stock Expense RestrictedStockExpense	724613	USD
CY2016	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	USD
CY2017	us-gaap	Availableforsale Securities Gross Unrealized Gain Loss1 AvailableforsaleSecuritiesGrossUnrealizedGainLoss1	-61519	USD
CY2016	us-gaap	Availableforsale Securities Gross Unrealized Gain Loss1 AvailableforsaleSecuritiesGrossUnrealizedGainLoss1	-971629	USD
CY2017	aytu	Issuanceofcommonstocktoexecutives Issuanceofcommonstocktoexecutives	509996	USD
CY2016	aytu	Issuanceofcommonstocktoexecutives Issuanceofcommonstocktoexecutives	0	USD
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	596434	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	428374	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	1507	USD
CY2016	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	91864	USD
CY2016	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2017	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	1750000	USD
CY2016	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	0	USD
CY2017	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	613309	USD
CY2016	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2017	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	16082	USD
CY2016	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	739857	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	90924	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2017	aytu	Proceedsfromissuanceofwarranttenderoffer Proceedsfromissuanceofwarranttenderoffer	2243282	USD
CY2016	aytu	Proceedsfromissuanceofwarranttenderoffer Proceedsfromissuanceofwarranttenderoffer	0	USD
CY2017	aytu	Paymentsforwarranttenderoffercost Paymentsforwarranttenderoffercost	312159	USD
CY2016	aytu	Paymentsforwarranttenderoffercost Paymentsforwarranttenderoffercost	0	USD
CY2017	aytu	Proceedsfromissuanceofcommonstockandwarrants Proceedsfromissuanceofcommonstockandwarrants	8602499	USD
CY2016	aytu	Proceedsfromissuanceofcommonstockandwarrants Proceedsfromissuanceofcommonstockandwarrants	7520493	USD
CY2017	aytu	Paymentsforregisteredofferingcosts Paymentsforregisteredofferingcosts	997865	USD
CY2016	aytu	Paymentsforregisteredofferingcosts Paymentsforregisteredofferingcosts	904914	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	2852	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2017	aytu	Fixedassetsincludedinaccountspayable Fixedassetsincludedinaccountspayable	10789	USD
CY2016	aytu	Fixedassetsincludedinaccountspayable Fixedassetsincludedinaccountspayable	0	USD
CY2017	aytu	Warrantsissuedinconnectionwithequityfinancingtoplacementagents Warrantsissuedinconnectionwithequityfinancingtoplacementagents	292630	USD
CY2016	aytu	Warrantsissuedinconnectionwithequityfinancingtoplacementagents Warrantsissuedinconnectionwithequityfinancingtoplacementagents	0	USD
CY2017	aytu	Warrantsamendedinconnectionwithwarranttenderoffer Warrantsamendedinconnectionwithwarranttenderoffer	63182	USD
CY2016	aytu	Warrantsamendedinconnectionwithwarranttenderoffer Warrantsamendedinconnectionwithwarranttenderoffer	0	USD
CY2016	us-gaap	Accretion Expense AccretionExpense	6000000	USD
CY2017	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	620325	USD
CY2016	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	620325	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Concentration of Business Risks</font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following counterparties contributed greater than  <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font></font>% of the Company's total revenue during the year ended June 30, 2017 and 2016, respectively. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The revenue from these counterparties as a percentage of total revenue was as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>86</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The loss of one or more of the Company's significant partners or collaborators could have a material adverse effect on its business, operating results or financial condition. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, management does not believe significant credit risk exists as of June 30, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We are also subject to credit risk from our accounts receivable related to our product sales. Historically, we have not experienced significant credit losses on our accounts receivable and we do not expect to have write-offs or adjustments to accounts receivable which would have a material adverse effect on our financial position, liquidity or results of operations. As of June 30, 2017, three customers accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60</font>% of gross accounts receivable. As of June 30, 2016, one customer accounted for <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 69</font>% of gross accounts receivable.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; BACKGROUND: transparent; FONT-SIZE: 11pt" align="center"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>Year Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer A</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer B</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer C</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="58%"> <div>Customer D</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>69</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	3900000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	41000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	7600000	USD
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	442000	USD
CY2016Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	77000	USD
CY2017Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	442000	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	USD
CY2017Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	738000	USD
CY2016Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	647000	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	41000	USD
CY2016Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	199000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	261155	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3610468	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10104425	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	7386782	USD
CY2016Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3869122	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5175000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-11000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0005	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.00	pure
CY2017Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	385000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	0	USD
CY2017	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	1900000	USD
CY2017	us-gaap	Restructuring And Related Cost Incurred Cost RestructuringAndRelatedCostIncurredCost	1500000	USD
CY2017Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	310000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	58000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	284000	USD
CY2017Q2	us-gaap	Restricted Cash RestrictedCash	4000000	USD
CY2017	aytu	Income Tax Reconciliation Of Fering Costs IncomeTaxReconciliationOfFeringCosts	203000	USD
CY2016	aytu	Income Tax Reconciliation Of Fering Costs IncomeTaxReconciliationOfFeringCosts	0	USD
CY2017	aytu	Effective Income Tax Rate Reconciliation Offering Costs EffectiveIncomeTaxRateReconciliationOfferingCosts	0.0090	pure
CY2016	aytu	Effective Income Tax Rate Reconciliation Offering Costs EffectiveIncomeTaxRateReconciliationOfferingCosts	0.00	pure
CY2017	aytu	Income Tax Reconciliation Contingent Consideration IncomeTaxReconciliationContingentConsideration	4000	USD
CY2016	aytu	Income Tax Reconciliation Contingent Consideration IncomeTaxReconciliationContingentConsideration	0	USD
CY2017	aytu	Effective Income Taxrate Reconciliation Contingent Consideration EffectiveIncomeTaxrateReconciliationContingentConsideration	0.0002	pure
CY2016	aytu	Effective Income Taxrate Reconciliation Contingent Consideration EffectiveIncomeTaxrateReconciliationContingentConsideration	0.00	pure
CY2017	aytu	Net Operating Losses Expiration Description NetOperatingLossesExpirationDescription	expire in 2031 through 2036.
CY2017	us-gaap	Description Of Defined Contribution Pension And Other Postretirement Plans DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans	The Company matches 50% of the first 6% contributed to the plan by employees.
CY2017Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	32800000	USD
CY2016Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17300000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	99000	USD
CY2017	aytu	Issuance Of Common Stock To Nuelle Share Holders IssuanceOfCommonStockToNuelleShareHolders	1837500	USD
CY2016	aytu	Issuance Of Common Stock To Nuelle Share Holders IssuanceOfCommonStockToNuelleShareHolders	0	USD
CY2017Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	191000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD

Files In Submission

Name	View Source	Status
0001144204-17-046061-index-headers.html	Edgar Link	pending
0001144204-17-046061-index.html	Edgar Link	pending
0001144204-17-046061.txt	Edgar Link	pending
0001144204-17-046061-xbrl.zip	Edgar Link	pending
aytu-20170630.xml	Edgar Link	completed
aytu-20170630.xsd	Edgar Link	pending
aytu-20170630_cal.xml	Edgar Link	unprocessable
aytu-20170630_def.xml	Edgar Link	unprocessable
aytu-20170630_lab.xml	Edgar Link	unprocessable
aytu-20170630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v473641_10k.htm	Edgar Link	pending
v473641_ex10-25.htm	Edgar Link	pending
v473641_ex23-1.htm	Edgar Link	pending
v473641_ex31-1.htm	Edgar Link	pending
v473641_ex31-2.htm	Edgar Link	pending
v473641_ex32-1.htm	Edgar Link	pending
v473641_img1.jpg	Edgar Link	pending
v473641_img10.jpg	Edgar Link	pending
v473641_img2.jpg	Edgar Link	pending
v473641_img3.jpg	Edgar Link	pending
v473641_img4.jpg	Edgar Link	pending
v473641_img5.jpg	Edgar Link	pending
v473641_img6.jpg	Edgar Link	pending
v473641_img7.jpg	Edgar Link	pending
v473641_img8.jpg	Edgar Link	pending
v473641_img9.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AYTU
AYTU BIOPHARMA, INC Stock $aytu

2017 Q3 Form 10-K Financial Statement

#000114420417046061 Filed on August 31, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU AYTU BIOPHARMA, INC Stock $aytu

2017 Q3 Form 10-K Financial Statement

#000114420417046061 Filed on August 31, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU
AYTU BIOPHARMA, INC Stock $aytu